tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Indaptus Therapeutics Approves Key Proposals at Annual Meeting

Story Highlights
Indaptus Therapeutics Approves Key Proposals at Annual Meeting

Elevate Your Investing Strategy:

Indaptus Therapeutics ( (INDP) ) has provided an announcement.

Indaptus Therapeutics held its Annual Meeting on June 10, 2025, where shareholders voted on several key proposals. The election of three Class I directors, the ratification of Haskell & White LLP as the independent accounting firm, the approval of executive compensation, and an amendment for a reverse stock split were all approved, indicating strong shareholder support for the company’s strategic decisions.

The most recent analyst rating on (INDP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.

Spark’s Take on INDP Stock

According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.

Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.

To see Spark’s full report on INDP stock, click here.

More about Indaptus Therapeutics

Average Trading Volume: 714,543

Technical Sentiment Signal: Sell

Current Market Cap: $5.28M

See more data about INDP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1